Home Cart Sign in  
Chemical Structure| 161801-60-1 Chemical Structure| 161801-60-1

Structure of ETA antagonist 1
CAS No.: 161801-60-1

Chemical Structure| 161801-60-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ETA antagonist 1 is a ETA selective antagonist with an IC50 of 0.08 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ETA antagonist 1

CAS No. :161801-60-1
Formula : C20H25N3O3S
M.W : 387.50
SMILES Code : O=S(C1=C2C=CC=C(NCCCCC)C2=CC=C1)(NC3=C(C)C(C)=NO3)=O
MDL No. :N/A

Safety of ETA antagonist 1

Related Pathways of ETA antagonist 1

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00796510 Pulmonary Arterial Hypertensio... More >>n Pulmonary Hypertension Less << Phase 3 Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) Less << - United States, California ... More >> Pfizer Investigational Site Fountain Valley, California, United States, 92708 Romania Pfizer Investigational Site Cluj Napoca, Romania, 400 001 Ukraine Pfizer Investigational Site Kyiv, Ukraine Less <<
NCT01658410 Coronary Artery Disease ... More >> Aorto-coronary Bypass Grafting Less << Phase 2 Unknown December 2016 Austria ... More >> Medical University of Vienna Vienna, Austria, 1090 Less <<
NCT00001527 - Completed - United States, Maryland ... More >> National Heart, Lung and Blood Institute (NHLBI) Bethesda, Maryland, United States, 20892 Less <<
NCT00796510 - Terminated(Safety Issue The tr... More >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) Less << - -
NCT00738049 Coronary Artery Disease ... More >> Endothelial Dysfunction Less << Phase 2 Completed - United States, Texas ... More >> Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital Houston, Texas, United States, 77030 Less <<
NCT02086253 Healthy Conditions Not Applicable Completed - France ... More >> CHU - Hôpitaux de Rouen Rouen, Normandy, France, 76031 Less <<
NCT00738049 - Completed - -
NCT00744211 - Completed - -
NCT00744211 Heart Disease Not Applicable Completed - United States, South Carolina ... More >> Ralph H. Johnson VA Medical Center, Charleston, SC Charleston, South Carolina, United States, 29401-5799 Less <<
NCT00260819 Hypoxia-Induced Pulmonary Arte... More >>ry Hypertension Less << Phase 1 Completed - France ... More >> Centre d'Investigation Clinique 9201 Hôpital Européen Georges Pompidou Paris, France, 75908 cedex 15 Less <<
NCT00111085 Aneurysmal Subarachnoid Hemorr... More >>hage Less << Phase 2 Completed - United States, Illinois ... More >> Dr. Giuseppe Lanzino Peoria, Illinois, United States United States, Indiana Dr. Horner Indianapolis, Indiana, United States United States, Maryland Dr. Aldrich Baltimore, Maryland, United States United States, Massachusetts Dr. Ogilvy Boston, Massachusetts, United States United States, Ohio Dr. Zuccarello Cincinnati, Ohio, United States Dr. Woo Cleveland, Ohio, United States United States, Pennsylvania Dr. Rosenwasser Philadelphia, Pennsylvania, United States Dr. Zager Philadelphia, Pennsylvania, United States United States, Texas Dr. George A. Lopez Houston, Texas, United States United States, Virginia Dr. Bullock Richmond, Virginia, United States Canada, Alberta Dr. Wong Calgary, Alberta, Canada Dr. Findlay Edmonton, Alberta, Canada Canada, British Columbia Dr. Redekop Vancouver, British Columbia, Canada Canada, Ontario Dr. Ferguson Toronto, Ontario, Canada Canada, Quebec Dr. Bojanowski Montreal, Quebec, Canada Canada Dr. Fleetwood Halifax, Nova Scotia, Canada Less <<
NCT00701597 Glaucoma Bloo... More >>d Flow Velocity Less << Phase 1 Completed - Austria ... More >> Department of Clinical Pharmacology, Medical University of Vienna Vienna, Austria, A-1090 Less <<
NCT01100736 Pulmonary Arterial Hypertensio... More >>n Vasodilation Vasoconstriction Less << Early Phase 1 Completed - United Kingdom ... More >> Clinical Research Centre, Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XU Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.58mL

0.52mL

0.26mL

12.90mL

2.58mL

1.29mL

25.81mL

5.16mL

2.58mL

 

Historical Records

Categories